I-MAB American Depositary Shares - IMAB STOCK NEWS

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has provided updates regarding the Holding Foreign Companies Accountable Act (HFCAA). As of March 8, 2022, I-Mab is not listed as a 'Commission-Identified Issuer' by the SEC. To ensure compliance, the company plans to engage an accounting firm subject to PCAOB inspection for its fiscal year 2022 audit. I-Mab is also pursuing a dual listing on the Hong Kong Stock Exchange to enhance trading flexibility for shareholders, pending market conditions and regulatory approvals.

I-Mab (Nasdaq: IMAB) announced multiple poster presentations at the AACR 2022 Annual Meeting, showcasing findings on enoblituzumab and TJ-C64B. Enoblituzumab, a monoclonal antibody targeting B7-H3, is under Phase 2 trials in China for solid tumors, and data highlights its anti-tumor activity and potential for combination therapies. TJ-C64B, a bispecific antibody, shows promise for treating CLDN6-positive tumors while minimizing liver toxicity. These presentations reflect I-Mab's commitment to advancing its innovative pipeline in cancer therapeutics.

I-Mab (Nasdaq: IMAB) announced FDA's Orphan Drug Designation for TJ-CD4B, a bispecific antibody targeting Claudin 18.2 for gastric cancer, including gastroesophageal junction cancer. This designation highlights potential therapeutic benefits and aims to expedite clinical development. TJ-CD4B demonstrated a strong tumor-killing effect and was well-tolerated in ongoing Phase 1 trials. Gastric cancer is a significant health issue, with 26,000 new cases annually in the U.S. and high mortality rates in China. Orphan Drug designation offers I-Mab various developmental benefits, including market exclusivity upon approval.

I-Mab (Nasdaq: IMAB) has announced a strategic partnership with Hangzhou Qiantang New Area to establish local manufacturing for its innovative drugs in China. This collaboration aims to expedite the commercialization of its assets, particularly felzartamab, which has shown positive clinical trial results for multiple myeloma. The new manufacturing facility is compliant with international standards, laying the groundwork for future drug supply and commercialization. I-Mab is positioning itself to meet the growing demand for effective cancer treatments in the region.

I-Mab (Nasdaq: IMAB) has announced the first patient dosing in its Phase 2 trial of lemzoparlimab combined with toripalimab for advanced solid tumors in China. This basket trial may lead to further registrational studies. Lemzoparlimab, a novel CD47 antibody, shows strong anti-tumor activity with minimal red blood cell binding, addressing challenges faced by similar therapies. The company aims to leverage translational findings to target tumors with a higher success probability. Ongoing studies in the U.S. and China explore various cancer treatments using lemzoparlimab.

I-Mab (Nasdaq: IMAB) announced that its senior management team executed a share purchase plan, acquiring over 70,000 American depositary shares (ADSs) for an aggregate of over US$2.6 million at an average price of approximately US$38 per ADS. The team aims to invest a minimum of US$3 million and up to US$20 million cumulatively in open market purchases, reflecting their strong confidence in the Company’s innovative pipeline and long-term growth prospects. I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases.

I-Mab (Nasdaq: IMAB) has initiated a Phase 2 clinical trial in China for efineptakin alfa (TJ107), a long-acting recombinant human interleukin-7, in combination with pembrolizumab (Keytruda®) for advanced solid tumors. This study targets multiple tumor types, including triple-negative breast cancer and squamous cell carcinoma of the head and neck. Efineptakin alfa aims to enhance anti-tumor T cell responses and addresses an unmet need in patients who poorly respond to current PD-(L)1 therapies. The trial will validate its safety and efficacy as part of I-Mab's advancing pipeline.

I-Mab (Nasdaq: IMAB) announced that its senior management team plans to purchase between US$3 million and US$20 million in the company's American depositary shares (ADSs) by February 28, 2022. This initiative reflects their confidence in the company's pipeline and business model, with expectations for continued progress in 2022. The management emphasized strong fundamentals following a year of significant clinical milestones. I-Mab aims to evolve from a clinical-stage firm to a fully integrated biopharmaceutical entity, bolstered by a diverse portfolio of over 20 drug candidates.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced its participation in several conferences in January 2022, including the 40th Annual J.P. Morgan Healthcare Conference, Morgan Stanley Virtual China New Economy Summit 2022, H.C. Wainwright Virtual BioConnect Conference, and UBS Greater China Conference 2022. Management will present and hold meetings with investors, featuring key executives including Dr. Jingwu Zang, Chairman and Acting CEO. These engagements aim to enhance visibility and foster relationships with investors.